You all make excellent points. I would suspect Guidelines will be soon include when when patients’ should have their tumor sent for molecular analysis. As a general role, we have been testing anyone with a Stage IIB or greater, knowing that the likelihood of relapse is high. The primary lesion is used. Having this information in our “pocket” in case….has saved time for those patients who have aggressive relapses. If not enough tissue is available or there is other concern for not proceeding with testing, we know that up front.
In an ideal world, having this knowledge expedites evaluation….but as we all know, we do not always live in an ideal world!